Core Viewpoint - The research published in the international ophthalmology journal "BMJ OPEN OPHTHALMOLOGY" evaluates and compares the vision-related quality of life and clinical efficacy of different optical interventions for myopic children and adolescents in China, providing important references for clinical choices in myopia optical intervention [1] Group 1: Industry Context - The prevalence of myopia among children and adolescents in China is increasing, characterized by younger onset and more severe cases, which has raised significant social concerns [1] - The company actively responds to the national initiative "Light Project" by collaborating with various institutions to address myopia prevention and control [1] Group 2: Technological Integration - The establishment of the "365 Myopia Prevention and Control System" incorporates new technologies such as big data, artificial intelligence, and genetics to create personalized intervention plans based on genetic testing and vision examination data [1] - The system covers the entire myopia development cycle, including prevention, early warning, control, and intervention, providing continuous management services [1]

Core Insights - Huaxia Eye Hospital (301267) reported a revenue of 2.139 billion yuan for the first half of 2025, representing a year-on-year growth of 4.31% [1] - The net profit for the same period was 282 million yuan, showing a year-on-year increase of 6.20% [1] - The basic earnings per share (EPS) stood at 0.34 yuan, with a weighted average return on equity (ROE) of 4.80% [1]

Core Insights - The research published in the international ophthalmology journal "BMJ OPEN OPHTHALMOLOGY" evaluates and compares the effectiveness and quality of life related to vision for children and adolescents wearing orthokeratology lenses (OK lenses), defocus glasses (DS glasses), and single vision glasses (SVS glasses) in China [1][2][3] Group 1: Research Findings - The study involved a cohort of 93 myopic children aged 7 to 17, divided into three groups wearing OK lenses, DS glasses, and SVS glasses, with a follow-up period of one year [1] - The results indicated significant differences in axial length growth among the three groups: the OK lens group showed an increase of only 0.18±0.08 mm, while the DS lens group had 0.27±0.08 mm, and the SVS lens group had 0.36±0.09 mm [2] - The OK lenses were found to control axial growth approximately 33% better than DS glasses and 50% better than SVS glasses, highlighting the advantages of newer lens types in preventing myopia progression [2] Group 2: Quality of Life Assessment - The study assessed quality of life using the internationally recognized "Children's Refractive Error Quality of Life Questionnaire" (PREP), which covers various dimensions such as distance vision, activity ability, and peer evaluation [1] - OK lenses demonstrated superior performance in multiple quality of life indicators, attributed to factors such as not needing to wear glasses during the day, unrestricted movement, reduced appearance anxiety, and clearer vision [2] - However, OK lenses had lower comfort scores compared to single vision glasses and required more complex maintenance, while DS glasses had lower scores in "near vision" due to their optical design [2] Group 3: Practical Implications - The research provides comprehensive insights for parents and doctors, indicating that while OK lenses have overall better performance, they may not be suitable for all children due to the need for strict screening of eye health and potential infection risks from improper maintenance [3] - DS glasses and SVS glasses are suggested to be more appropriate for children in conditions with limited hygiene or those unable to comply with nighttime lens wear [3]

Group 1: Market Potential and Growth - The elderly population in China is expected to exceed 400 million by 2035, indicating a rapid aging process and significant market potential for the silver economy, projected to reach 30 trillion yuan [1] - In 2025, the sales revenue of elderly care services, elderly-friendly household services, and elderly social care services is expected to grow by 40.9%, 14.1%, and 8.8% respectively, significantly outpacing the average growth rate of the service industry [2] - As of now, 49,640 new elderly care-related enterprises have been established in China this year, with a total of 596,100 elderly care enterprises, reflecting strong market recognition of the silver economy sector [1][2] Group 2: Technological Integration - The role of technology, particularly data technology, is becoming increasingly crucial in the elderly care sector, transitioning from an auxiliary tool to a core driving force [3] - Smart monitoring devices, such as health monitoring equipment from Lepu, are being utilized to track vital signs of the elderly, providing real-time data and alerts for medical emergencies [3] Group 3: Policy Support and Capital Investment - Government policies are actively promoting the development of elderly care services, with financial incentives such as construction and operational subsidies for new elderly care institutions [4] - The capital market is increasingly focused on the silver economy, with 56 related enterprises raising 216.43 billion yuan through initial public offerings, and 17 elderly-themed bonds raising 11.82 billion yuan [5][6] Group 4: Consumer Awareness and Market Dynamics - Despite the positive growth trajectory, consumer awareness remains a significant barrier to unlocking the full potential of the silver economy, with many elderly individuals lacking understanding of healthcare products [6] - Companies are adopting experiential marketing and educational initiatives to enhance elderly consumers' understanding of medical products, while local governments are facilitating access to elderly-friendly products through subsidies [7]

Group 1 - The company, Huaxia Eye Hospital Group Co., Ltd., has announced that it will not distribute cash dividends, issue bonus shares, or increase capital reserves during the reporting period [2][3] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [4] - The company completed the distribution of cash dividends amounting to RMB 183,143,875.20 on July 14, 2025, with a distribution of RMB 2.20 per 10 shares [4]

Meeting Overview - The third board meeting of Huaxia Eye Hospital Group Co., Ltd. was held on August 21, 2025, combining both in-person and remote attendance [1] - All 7 board members attended the meeting, with one member represented by proxy due to personal reasons [1] - The meeting was chaired by Mr. Chen Fengguo, and it complied with relevant regulations [1] Resolutions Passed - All resolutions were passed unanimously with 7 votes in favor, 0 against, and 0 abstentions [2][3][4] - The resolutions included the approval of the semi-annual report and the special report on the management and use of raised funds [2][4] - A proposal to amend the company's articles of association was approved, which will eliminate the supervisory board, transferring its powers to the audit committee of the board [2][4] Future Actions - Several resolutions are pending submission to the shareholders' meeting for further approval [2][3][4] - The company will publish detailed information regarding the resolutions on its official website [5]

| 2025 | | 华厦眼科医院集团股份有限公司 | 年半年度报告摘要 | | | --- | --- | --- | --- | --- | | 证券代码：301267 | | 证券简称：华厦眼科 | 公告编号：2025-025 | | | 华厦眼科医院集团股份有限公司 | | | | | | 华厦眼科医院集团股份有限公司 | | | | 2025 年半年度报 | | 告摘要 | | | | | | 一、重要提示 | | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | | 资者应当到证监 | | | | | | 会指定媒体仔细阅读半年度报告全文。 | | | | | | 除下列董事外，其他董事亲自出席了审议本次半年报的董事会会议 | | | | | | 未亲自出席董事姓名 | | 未亲自出席董事职务 | 未亲自出席会议原 | | | 因 | | 被委托人姓名 | | | | 苏庆灿 | | 董事长 | 因个人原 | | | 因 | | 陈凤国 | | | | 非标准审计意见提示 | | | | | | □适用 | ?不适用 | ...

Meeting Overview - The third supervisory board meeting of Huaxia Eye Hospital Group Co., Ltd. was held on August 21, 2025, combining both in-person and remote attendance [1] - All three supervisors attended the meeting, which was chaired by Ms. Huang Niya, and complied with relevant regulations [1] Resolutions Passed - The supervisory board unanimously approved the written confirmation of the 2025 semi-annual report, ensuring its authenticity and completeness, with a voting result of 3 in favor, 0 against, and 0 abstentions [1] - The supervisory board confirmed that the report on the management and use of raised funds for the first half of 2025 accurately reflects the company's situation and complies with legal requirements, with the same voting result [2] - The board agreed to extend the implementation period for certain fundraising projects, stating that this does not change the amount of funds or the direction of investment, nor does it materially affect the company's financial status or shareholder interests, with a voting result of 3 in favor, 0 against, and 0 abstentions [2][3]

证券代码：301267 证券简称：华厦眼科 公告编号：2025-029 华厦眼科医院集团股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日召开了第三届董事会第十次会议，决定于 2025 年 9 月 10 日（星期三）召开公 司 2025 年第一次临时股东会，本次股东会采用现场表决与网络投票相结合的方 式召开，现将本次会议的有关事项通知如下： 一、召开会议的基本情况 于提请召开 2025 年第一次临时股东会的议案》，本次股东会会议的召开符合有 关法律、行政法规、部门规章、规范性文件、业务规则和《公司章程》等相关规 定。 （1）现场会议时间：2025 年 9 月 10 日（星期三）下午 15:00； 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 10 日 9:15-9:25、9:30-11:30 和 13:00-15:00； 公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp ...

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 部分募集资金投资项目延长实施期限的核查意见 中国国际金融股份有限公司（以下简称"中金公司"、"保荐机构"）作为华厦眼科医 院集团股份有限公司（以下简称"华厦眼科"或"公司"）首次公开发行股票并在创业板上 市及持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资 金监管规则》 《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和规范性文件的规定， 对华厦眼科部分募集资金投资项目延长实施期限的事项进行了审慎核查，具体情况如下： 一、募集资金投资项目的基本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次公开发 行股票注册的批复》 （证监许可〔2022〕2085 号）同意，公司首次公开发行人民币普通 股（A 股）6,000.00 万股，每股发行价为人民币 50.88 元，募集资金总额为人民币 净额为人民币 276,849.25 万元。上述募集资金已于 2022 年 10 月 28 日到账，容诚会计 师事务所（特殊普通合伙）对募集资金到位 ...